Compare Tango Therapeutics Inc. (TNGX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Zscaler Inc — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Zscaler Inc trades at $214.06 (market cap $36.00B). The key difference: Zscaler Inc is far larger — about 9.6× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Zscaler Inc for 41 Days on average.
| TNGX | ZS | |
|---|---|---|
Market Cap | $3.74B | $36.00B |
Volume | 3,438,781 | 2,901,773 |
Sector | Health | Technology |
52-Week High | $32.90 | $336.27 |
52-Week Low | $7.50 | $118.05 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $2.76B | $34.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Zscaler (ZS) trades at $228.66, up 1.28% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -1.88% net margin. Recent earnings beats and 79.6% analyst buy ratings support optimism, while the stock faces headwinds from executive turnover and negative cash flow projections for 2026.
ZS presents a growth-focused opportunity in cybersecurity with AI-driven bookings up 50% sequentially, but investors must weigh high valuations (P/S 10.79) against persistent profitability challenges and near-term execution risks following the chief revenue officer departure. The consensus price target of $222.83 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
